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The Zika virus is the primary suspect in the large increase in incidence of microcephaly in 2015-6
in Brazil, however its role is not confirmed despite individual cases in which viral infections were
found in neural tissue. Here we consider the alternative possibility that the use of the insecticide
pyriproxyfen for control of mosquito populations in Brazilian drinking water may actually be the
cause. Pyriproxifen is a juvenile hormone analog which has been shown to correspond in mammals
to a number of fat soluble regulatory molecules including retinoic acid, a metabolite of vitamin
A, with which it has cross-reactivity and whose application during development has been shown
to cause microcephaly. Methoprene, another juvenile hormone analog that was approved as an
insecticide based upon tests performed in the 1970s, has metabolites that bind to the mammalian
retinoid X receptor, and has been shown to cause developmental disorders in mammals. Isotretinoin
is another example of a retinoid causing microcephaly in human babies via maternal exposure and
activation of the retinoid X receptor in developing fetuses. Moreover, tests of pyriproxyfen by the
manufacturer, Sumitomo, widely quoted as giving no evidence for developmental toxicity, actually
found some evidence for such an effect, including low brain mass and arhinencephaly—incomplete
formation of the anterior cerebral hemispheres—in exposed rat pups. Finally, the pyriproxyfen use
in Brazil is unprecedented—it has never before been applied to a water supply on such a scale.
Claims that it is not being used in Recife, the epicenter of microcephaly cases, do not adequately
distinguish the metropolitan area of Recife, where it is widely used, and the municipality, where it is
not. Given this combination of information about molecular mechanisms and toxicological evidence,
we strongly recommend that the use of pyriproxyfen in Brazil be suspended until the potential causal
link to microcephaly is investigated further.
I. OVERVIEW
In 2015 and early 2016 over 6,000 suspected cases
of microcephaly and other neurodevelomental disorders
have been reported in Brazil, primarily in the north-
east, a dramatic increase over expected numbers [1]. The
cause of these developmental disorders has been widely
attributed to a Zika virus epidemic first detected in May,
2015 [2]. While evidence exists, particularly in neurologi-
cal infections of a few microcephalic cases [3, 4], only 12%
of confirmed microcephaly cases have also been confirmed
as having Zika infections [1], preventing health authori-
ties from determining a conclusive causal link [5, 6]. The
strongest potential counter evidence is present in the ge-
ographic distribution of cases, including an absence of
cases in Colombia. In the first 12 full weeks of 2016,
34 cases of microcephaly have been identified in Colom-
bia [7, 8], compared to 32 cases expected based upon
140 annual background cases, and not indicative of the
two orders of magnitude larger number of cases found
in northeast Brazil. Of the 34 cases of microcephaly 7
have been reported to have positive Zika tests [8] with
the rest under investigation. Another widely reported
case in Panama [10] is consistent with background rates.
Reporting of the Colombia Zika outbreak began in Oc-
tober [2]. If Zika is the cause many more cases will be
appearing shortly. If more cases of microcephaly are not
reported by June/July of 2016 then this would be ev-
idence against the causal link of Zika to microcephaly
[11]. A prior outbreak in French Polynesia has been ret-
rospectively analyzed [12]. The best fit model implies
increased incidence of microcephaly resulting from ma-
ternal exposure in the first trimester of pregnancy, pro-
viding strong statistical evidence, though the few cases
(seven during the critical period corresponding to a 1%
incidence) may not be conclusive, and the interpreta-
tion is complicated by the inclusion of still-births and
aborted fetuses. Including just live births would yield
only one microcephaly case over background. A prelim-
inary cohort report on outcomes of Zika infected preg-
nant women in Rio de Janeiro appears to provide strong
evidence [13], however, two of the four cases in which mi-
crocephaly is reported through ultrasonographic features
are associated to infections in the 5th and 6th months
of pregnancy, inconsistent with both the French Polyne-
sian analysis showing primarily early pregnancy effects
and with the absence of reported cases in Colombia. In-
deed, while 4 out of 23 pregnancies are reported as having
anomalous ultrasounds when exposures happened in the
first 4 months, 3 out of 9, (5 out of 9) pregnancies re-
ported as infected in the 5th (6th or later) month have
anomalies, including 2 still births in addition to the mi-
crocephalic ultrasounds [14]. If similar exposure impacts
were present in Colombia, a large number of anomalies,
still births and microcephalies would already be reported.
The seemingly inconsistent two late term microcephaly
cases were eventually reported as small for gestational
age rather than microcephaly at birth. While this might
help resolve some of the discrepancy with Colombia, dis-
counting the ultrasonographic findings leaves only one
live microcephaly birth in the report. Finally, the Zika
infected and small uninfected populations of the study
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2are low/high income biased and therefore may also be
to environmental exposures of teratogenic agents asso-
ciated with mosquito control that correlate with areas
that have higher likelihood of infection. Perhaps most
puzzling, the reported tracking of microcephaly through
ultrasound during pregnancy in these two studies seems
inconsistent with the absence of reports in Colombia.
Thus, while it is possible that a complete picture con-
sistent with Zika as the cause can be constructed with
available information, questions remain and full confir-
mation is not yet possible. Alternative hypotheses about
causes of microcephaly should still be considered.
A group of physicians in Argentina and Brazil have
suggested that widespread use of the pesticide pyriprox-
ifen [15] to reduce mosquito populations because of a
dengue epidemic in 2014 may be the cause of micro-
cephaly [16]. This suggestion has been challenged both
by authorities based upon a claim of lack of evidence
[17, 18] and by skeptics of conspiracy theories [19]. We
have previously reviewed the primary evidence [6], in-
cluding evidence in rat toxicology studies performed
by its manufacturer Sumitomo [20], concluding that
pyriproxifen is a credible candidate so that further in-
quiry is warranted.
Here we discuss the molecular mechanisms associated
with pyriproxyfen in insect and mammalian development
and summarize toxicological studies and insecticide use
in Brazil. Of particular note is that pyriproxyfen, a bio-
chemical analog of juvenile hormone in insects, is cross-
reactive with the retinoic acid / vitamin A regulatory
system of mammals, and that exposure to retinoic acid
has been shown to cause microcephaly [21]. Existing tox-
icological studies and experience with public use do not
provide evidence to counter this causal chain. Toxicolog-
ical studies, if anything, provide evidence for neurodevel-
opmental toxicity at a level consistent with that found
for microcephaly in Brazil. The use of pyriproxyfen in
the water supplies in Brazil is at an unprecedented scale
and neither prior studies nor experience is able to pro-
vide information about its effects. Our review of the
currently available information points to both adequate
reasons to suspect this insecticide as a developmental dis-
ruptor causing microcephaly and inadequate testing of its
toxicology or use in water supply.
II. POTENTIAL CAUSES AND TIMELINE
The World Health Organization (WHO) identifies the
most common causes of microcephaly as [22]: infections,
exposure to toxic chemicals, genetic abnormalities, and
severe malnutrition while in the womb. The first includes
toxoplasmosis, which is caused by parasites in under-
cooked meat, rubella, herpes, syphilis, cytomegalovirus
and HIV. The second includes exposure to heavy metals,
such as arsenic and mercury, as well as alcohol, smoking
and radiation exposure. The third may include problems
such as Down syndrome. While the first category points
to the possibility of infectious causes, the second points
to the possibility of chemical ones.
The suspected association of increased microcephaly
cases with Zika and pyriproxyfen relies first on an in-
crease in the cause with the increase in number of cases.
The outbreak of the former was recognized in May 2015,
and the use of the latter in the fourth quarter of 2014,
with the incidence of microcephaly cases beginning in Oc-
tober of 2015. The precise dates of the increase in cases
are believed to be uncertain because of potential prob-
lems with underreporting prior to the medical alert and
overreporting afterwards [5].
III. PYRIPROXYFEN MOLECULAR
MECHANISMS
Juvenile hormone and retinoic acid are both lipid-
soluble terpenoids. They act as signaling molecules that
control a broad diversity of embryonic and postembry-
onic developmental processes in insects and vertebrates,
respectively. Juvenile hormone is best known for its role
in the control of metamorphosis and reproduction in in-
sects [23, 24], whereas retinoic acid is involved in the
development of the nervous system in vertebrates [25].
These two classes of hormone-like molecules share some
molecular similarities and are capable of some degree of
cross-reactivity. For instance, retinoic acid is known to
mimic some of the effects of juvenile hormone when in-
jected into insects [26], and juvenile hormone and its
analogs are known to bind to the vertebrate retinoic acid
receptor [27–29]. It is possible therefore that pyriprox-
ifen, a powerful juvenile hormone analog [30], can bind
to the retinoic acid receptor. When it does so it could
either activate the receptor at inappropriate times in de-
velopment, or act as a blocker that prevents the normal
retinoic acid from binding to the receptor when needed.
The retinoic acid receptor normally turns on gene ex-
pression in development, so either an inappropriate ac-
tivation, or an inhibition at a critical time, could be ex-
pected to lead to developmental abnormalities.
More specifically, another juvenile hormone analog
that has been approved as an insecticide, methoprene,
has also been shown to have metabolites that bind to the
mammalian retinoid X receptor, and has been shown to
cause developmental disorders in mammals [29, 31].
Isotretinoin is a retinoid that is widely used in
medicine, but counter indicated in women who are preg-
nant or might become pregnant. It causes microcephaly
in human babies via maternal exposure and activation of
the retinoid X receptor in developing fetuses [32, 33].
The impact of retinoids on abnormal development (ter-
atogenesis) has been demonstrated to be sensitive to
genotype, developmental stage of exposure, and to re-
sult in death, malformation, growth retardation, and/or
functional disorder [34]. The juvenile hormone itself and
different juvenile hormone analogs have different binding
properties to mammalian retinoic acid receptors, which
3could therefore produce different effects, including terato-
genicity. These effects remain poorly understood [24, 35].
IV. TOXICOLOGICAL STUDIES
The potential link between pyriproxyfen and micro-
cephaly has been challenged based upon the existence
of toxicological studies by the manufacturer Sumitomo.
However, we have reviewed their studies and find them
largely restricted to analysis of the impact on adult ani-
mals. In the experiments on developmental toxicity, the
ability to identify a link to microcephaly is weak based
upon the specific tests that have been performed. Rather
than measurements, in most tests visual macroscopic ob-
servation of rat and rabbit fetuses or pups/kits were used
[36], for which standards of microcephaly determination
may not be sufficiently well established or comparable
across species. Still, in the most relevant experiment
there is a reported test of brain weight and neurodevel-
opmental disorders in rat pups, and in that study, there
is actual evidence for microcephaly.
Specifically, the most relevant study to a determination
of neurodevelopmental toxicity [20] considered brain and
behavioral effects of rat pups exposed to pyriproxyfen
during days 7 to 17 of gestation, which lasts 21 days.
The experimental group of 36 pregnant rats in each of
four test groups were fed dosage levels of 0, 100, 300 and
1000 mg/kg/day. The pups were checked for physiologi-
cal deformations and organs weighed.
From each dosage level litters of pups were obtained.
For 99 pups in the 100 mg/kg and 78 pups of the 1000
mg/kg dosage groups no relevant developmental disor-
ders were reported. Of the 99 pups in the 300 mg/kg
dosage 1 (1%) had Arhinencephaly and 1 (1%) had Thy-
roid hypoplasia, The former would be consistent with
concerns about neurodevelopmental disorders of the type
of microcephaly.
Of the resulting offspring, 2 male and 2 female per
dosage were kept alive for emotional/mental testing at 4
and 6 weeks of age and their brains were subsequently
weighed at 8 weeks. One of the groups, the males of
the 300 mg/kg group, had statistically significant lower
brain weight at 8 weeks, implying that at least one of the
only 12 pups tested in this way had substantially reduced
brain weight.
These tests provide evidence that microcephaly may be
an outcome of the application of pyriproxyfen to rats and
other mammals. The conventional toxicology assump-
tions of dose dependence used in interpreting these re-
sults infer from the absence of similar observations in the
1000 mg/kg dosage group that the cases in the 300 mg/kg
group are not relevant [36]. This assumption may not be
reliable due to genetic variability, regulatory sensitivity,
and limited numbers of observations. Instead, the out-
comes might be interpreted as an estimated probability of
incidence of 1 in 12. Considering the differences between
humans and rats, the values for humans may be higher or
lower than this. Note that the incidence of microcephaly
in Brazil is estimated to be 1% [1]. The need for care-
ful studies is apparent in that tetragonicity of a retinoid
varies widely across mammalian species, and this varia-
tion varies across different retinoids [33, 37–40]. Regula-
tory systems are remarkably sensitive to small molecular
densities. Given the low incidence of human cases of
microcephaly in affected populations, experiments that
are designed to test for microcephaly in mammals, at
the very least, should be designed to identify incidence
at this level. Moreover, they should be unambiguously
capable of detecting microcephaly.
Finally, there are multiple drugs that passed conven-
tional regulatory animal testing and are now known
to be linked to microcephaly, including phenytoin and
metotrexate [41–43], so that assurances based solely upon
conventional regulatory testing are inadequate.
V. USE OF PYRIPROXYFEN IN WATER
SUPPLY IN BRAZIL
Pyriproxyfen has been used as an insecticide in north-
east Brazil in response to an outbreak of dengue starting
in the fourth quarter of 2014 [44]. It is applied primarily
to water storage containers used for home drinking water
in areas that do not have a municipal water supply.
The potential link between pyriproxyfen and micro-
cephaly has been challenged based upon its use in other
parts of the world. Pyriproxyfen is an insecticide that
has received widespread regulatory approval [45, 46]. It
is used on agricultural crops [47], and against insects in
households and pets, e.g., on pet collars [48]. The use
of pyriproxyfen in the water supply in Brazil, however,
does not have precedent. It was tested in a few com-
munities in Malaysia [49], Peru [50], Colombia [51] and
Cambodia [52]. These were small case studies and only
Cambodia and Colombia included use in the drinking
water supply [49]. Moreover, the research on impacts in-
cluded measures of mosquito control but did not consider
developmental effects in humans.
Prior to 2014, Brazil primarily used temefos (an
organophosphate) in water supplies to reduce mosquito
populations. The switch to pyriproxyfen was made due
to increasing temefos resistance in mosquitoes [53]. Some
areas of Brazil do not use pyriproxyfen, using BT Toxin
instead. The Brazilian Ministry of Health has suggested
that areas not using pyriproxyfen also report cases of mi-
crocephaly. For example, there is reported to be no use
of pyriproxyfen in Recife, and two other cities of the state
of Pernambuco [54–56], though there are cases of micro-
cephaly and Zika. This has been cited as a compelling
reason for dismissing the possibility that pyriproxyfen
is a cause of microcephaly [56]. However, according to
the Dengue control office of Pernambuco, pyriproxyfen
is widely used in the Recife metropolitan area. It is not
used in three specific municipalities (urban administra-
tive areas), specifically Recife, Paulista and Jaboatao do
4Guararapes. Pyriproxyfen exposure is relevant for the
urban favelas and nearby rural areas where it would be
used in water storage containers but is not relevant to
urban areas with municipal water supply systems. Ur-
ban hospitals attract populations from a large area [57]
and official reporting of cases is not broken down by mu-
nicipality but rather by state, so that a direct analysis of
geographical distribution of exposure to pyriproxyfen is
difficult in these particular cases. Thus, further analysis
is needed to determine whether the large number of cases
in Pernambuco state arises from areas where pyriprox-
yfen is used.
VI. CONCLUSION
This paper analyzes the potential causal connection
between the pesticide pyriproxyfen and microcephaly, as
an alternative to Zika. Pyriproxyfen is a juvenile hor-
mone analog, which has been shown to be cross reac-
tive with retinoic acid, part of the mammalian regulatory
system for neurological development, whose application
during development causes microcephaly. This causal
chain provides ample justification for pursuing a careful
research effort on the role of pyriproxyfen in neurodevel-
opmental disorders. Counter to stated claims, existing
studies of neurodevelopmental toxicity by Sumitomo, its
manufacturer, provide some supportive evidence for neu-
rodevelopmental toxicity including low brain weight in
rat pups. The large-scale use of pyriproxyfen in Brazil
and its coincidental timing with an increase in micro-
cephaly cases should provide additional motivation. We
believe that this evidence is strong enough to warrant
an immediate cessation of pyriproxyfen application to
Brazilian water supplies until additional research can be
carried out on its neurodevelopmental toxicity. Where in-
secticides are considered essential, Bt toxin is considered
a safe alternative that has been used in water systems
in Recife since 2002 [58]. Other more effective vector
control methods may also be used [59–61].
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